Eswatini vs Zimbabwe: Average cost of multi drug-resistant tuberculosis treatment
Eswatini
840 constant 2022 US$
in 2024
Zimbabwe
851 constant 2022 US$
in 2023
Eswatini rank
59th
Zimbabwe rank
57th
Average cost of multi drug-resistant tuberculosis treatment over time
- Eswatini
- Zimbabwe
How they compare
Zimbabwe currently reports 851 constant 2022 US$ against 840 constant 2022 US$ in Eswatini, a difference of 11 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Eswatini ahead.
Eswatini ranks 59th and Zimbabwe ranks 57th of 92 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,118 constant 2022 US$ | 1,672 constant 2022 US$ | 4,446 constant 2022 US$ | Eswatini |
| 2020s | 3,320 constant 2022 US$ | 696.25 constant 2022 US$ | 2,624 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eswatini or Zimbabwe?
- Zimbabwe, at 851 constant 2022 US$ against 840 constant 2022 US$ in Eswatini as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eswatini and Zimbabwe?
- 11 constant 2022 US$, with Zimbabwe ahead.
- How many years of comparable data are there for Eswatini and Zimbabwe?
- 7 years are reported by both, from 2017 to 2023.
- How do Eswatini and Zimbabwe rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eswatini ranks 59th and Zimbabwe ranks 57th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.